Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
← catalyst calendarNCT05226871 · readout in 134 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
35actual
Sites
23
Countries
China, Mexico, South Korea +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-07 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Head and Neck Cancer
Interventions
- Drug: Palbociclib — also filed as IBRANCE
- Drug: Cetuximab
- Drug: Fulvestrant
- Drug: Letrozole
Primary outcome
what the primary-completion date above is the date OFNumber/Percentage of Participants with Treatment-Emergent Adverse Events (AEs) Leading to Permanent Discontinuation of Study Treatment and Serious Adverse Events (SAEs)
measured Baseline up to 28 days after last dose of study intervention
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed